Buprenorphine Microspheres High Drug Load Solvent System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current buprenorphine delivery methods, such as sublingual tablets and transdermal patches, face challenges like withdrawal symptoms due to fluctuating drug concentrations, low drug load in microsphere formulations, and the use of toxic solvents in injectable formulations, which affect patient compliance and manufacturing viability.
Innovation Solution
A method for producing a sustained release buprenorphine microsphere formulation with a high drug load and low initial burst release, using a continuous oil-in-water emulsion process with an encapsulating polymer, a primary solvent, and a co-solvent like benzyl alcohol to enhance solubility, resulting in microspheres with a drug load of 35-55% and controlled release over one to nine months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional microsphere formulations are used to achieve sustained release, then withdrawal symptoms are prevented, but the drug load is too low (less than 2%) to be commercially viable
Solution Approach 1:
The patent changes the chemical parameters of the solvent system by introducing a co-solvent (benzyl alcohol) to increase buprenorphine solubility in the dispersed phase. This allows higher drug loading (35-55%) while maintaining the sustained release mechanism through controlled solvent diffusion and polymer matrix formation.
Solution Approach 2:
The patent uses a composite solvent system comprising a primary solvent (methylene chloride) and a co-solvent (benzyl alcohol). This composite system provides both high drug solubility and controlled release properties, enabling high drug load while maintaining sustained release effectiveness.
2Quantity of substance
If additional polymer coating is applied to increase drug load, then drug encapsulation is improved, but manufacturing complexity and difficulty increase
Solution Approach 1:
The patent merges the drug encapsulation function and the structural framework function into a single polymer matrix step. By incorporating buprenorphine directly into the PLGA microsphere matrix during formation, the patent eliminates the need for separate coating operations, reducing manufacturing complexity while achieving high drug load (35-55%).
3Duration of action of moving object
If toxic solvents like N-methyl pyrolidone are used in injectable formulations, then sustained release is achieved, but the formulation becomes unsafe for human use
Solution Approach 1:
The patent extracts the toxic component (N-methyl pyrolidone) from the solvent system and replaces it with a non-toxic alternative (benzyl alcohol as co-solvent). This maintains the sustained release mechanism while eliminating the harmful factor, making the formulation safe for human use.
Solution Approach 2:
The patent introduces benzyl alcohol as an intermediary co-solvent that mediates between the hydrophobic polymer matrix (PLGA) and the hydrophilic drug (buprenorphine). This intermediary enables high drug solubility and controlled release without the toxicity of traditional solvents like N-methyl pyrolidone.
4Quantity of substance
If high drug load microspheres are produced without co-solvent, then manufacturing is simpler, but initial burst release is high and sustained release is not achieved
Solution Approach 1:
The patent changes the solvent composition parameter by adding benzyl alcohol as a co-solvent. This modification controls the solubility and diffusion characteristics of buprenorphine, reducing initial burst release and achieving a stable sustained release profile over 1-9 months while maintaining high drug load (35-55%).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a high drug encapsulation efficiency (>80%) and controlled release of buprenorphine, minimizing initial burst release and using non-toxic solvents, thereby improving patient compliance and manufacturing efficiency.
Implementation Method 1
a co-solvent capable of increasing the solubility of the buprenorphine relative to the dispersed phase
Implementation Method 2
mixing the dispersed phase with the continuous phase
Implementation Method 3
Upon injection, the solvent diffuses away from the injection site, leaving the buprenorphine containing polymer matrix
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.